ash 2018: selinexor study - storm myeloma trial results
Published 5 years ago • 276 plays • Length 4:07Download video MP4
Download video MP3
Similar videos
-
2:03
ash 2018: selexinor results in tow trials: storm and stomp
-
8:26
ash 2018: selinexor, daratumumab and dexamethasone for relapsed/refractory myeloma
-
1:03:56
selinexor combinations in clinical trials with dr. jeffrey zonder
-
54:41
exploring the selinexor stomp trial
-
10:16
selinexor in multiple myeloma — dr. joshua richter | mcrt webcast july 11
-
1:21
ash 2018: bite clinical trial in relapsed/refractory multiple myeloma
-
5:51
understanding selinexor: david siegel, md, phd
-
2:48
a combined analysis of the storm and mammoth studies
-
1:28
ash 2018: using exercise (even resistance training) in multiple myeloma patients
-
3:05
refractory multiple myeloma: analyzing mammoth and storm
-
2:16
selinexor prior to car-t cell therapy in myeloma | bruno costa, md | ims 2024
-
4:08
what is the latest on a new drug called selinexor?
-
3:45
ash 2018: fighting myeloma resistance with personalized 3d tumor modeling
-
2:04
ash 2018: earlier smoldering myeloma treatment & the promise study
-
13:22
efficacy and toxicity of selinexor: importance of dose intensity and post progression outcomes
-
3:52
overall survival with oral selinexor low dose dex in pts with triple class refractory-mm
-
4:00
top multiple myeloma research presented at ash 2018
-
1:53
istopmm study and early mgus and smm screening | joshua richter, md | ash 2021
-
6:24
michael kauffman, md, phd discusses selinexor data presented at ash 2018